Generate Biomedicines Inc logo

Generate Biomedicines Inc

GENB
Healthcare|Biotechnology|USA
$14.32
-1.40 (-8.87%)

Clinical Trials (7)

TrialConditionsPhaseStatusEnrollmentDesignDrug
NCT07359846
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
Severe Asthma
P3
Recruiting786RCT, Double-blindGB-0895, Placebo
NCT07276724
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
Severe Asthma
P3
Recruiting786RCT, Double-blindGB-0895, Placebo
NCT07489287
GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
Platinum-resistant Ovarian Cancer
P1
Recruiting18Open-labelGB-5267 - IV only, GB-5267 -Combined IV and IP Infusion
NCT06920693
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants
Atopic Dermatitis (AD)
P1
Active40RCT, Double-blindGB-7624, Placebo
NCT07116889
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
Asthma, COPD (Chronic Obstructive Pulmonary Disease)
P1
Active156RCT, Double-blindGB-0895 (SC), GB-0895 (SC), Placebo (SC), Placebo (SC)
NCT07484022
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
P1
Recruiting37Open-labelGB-4362, enfortumab vedotin (EV), Pembrolizumab
NCT07050511
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants
SARS CoV-2
P1
Completed51Double-blindGB-0669, Placebo